TG Therapeutics, Inc. (TGTX)

NCM – Real Time Price. Currency in USD

55.83

+2.20 (4.10%)

At close: Jun 26, 2026, 4:00 PM EDT

55.80

-0.03 (-0.05%)

After-hours: Jun 26, 2026, 7:59 PM EDT

17.06.2026

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.

11.06.2026

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

10.06.2026

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.

09.06.2026

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

09.06.2026

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)

05.06.2026

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?

04.06.2026

TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi

TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.

Videos

No Data

There is no data to display

Press releases

09.06.2026

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)

03.06.2026

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027

02.06.2026

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026.

01.06.2026

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy therapy NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in treatment-naïve adult patients with relapsing forms of multiple sclerosis (RMS).

TG Therapeutics, Inc. (TGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TG Therapeutics, Inc. (TGTX)

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi

Videos

No Data

Press releases

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi

Videos

No Data

Press releases

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Search stocks

TG Therapeutics, Inc. (TGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TG Therapeutics, Inc. (TGTX)

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi

Videos

No Data

Press releases

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi

Videos

No Data

Press releases

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology